It came as something of a surprise when Health and Human Services Secretary Alex Azar announced that the administration was exploring the importation of prescription drugs to fight high domestic prices. Azar and Scott Gottlieb, commissioner of the Food and Drug Administration, who also endorsed the new proposal, had previously opposed the idea.

LHC Group today announced the finalization of two equity partnership agreements to purchase and share ownership of home health and hospice services locations with regional health system providers in the markets of Reno, Nev., and Jefferson City, Mo.

Think President Donald Trump's proposal to slap price tags on drug advertising is all talk and no action? Think again. Over the past couple of weeks, the idea has gained steam—and bipartisan backing, including from Democrats often critical of the president. So much so, in fact, that a bill containing the provision could see a Senate vote this week.

As the CMS charts a path to level pay for outpatient services, it's also leading toward a head-to-head battle with powerful hospital lobbying groups as some providers win and lose with site-neutral payments.

The U.S. is grappling with how to rein in high drug prices. Unfortunately, most of the proposed solutions work better on a bumper sticker than in reality. The debate, however, tends to ignore a key player -- the prescribing doctor -- who could have a central role in a more sustainable approach to better value in drug pricing.

One year ago, with the flick of his thumb, Sen. John McCain (R-Ariz.) foiled the Republican Party’s quest to undo the Affordable Care Act and fulfill a seven-year promise to remake the health-care system.